Loading...
XTAI
4108
Market cap74mUSD
Jul 09, Last price  
12.00TWD
1D
-0.83%
1Q
-4.38%
Jan 2017
-60.72%
IPO
-70.47%
Name

Phytohealth Corp

Chart & Performance

D1W1MN
XTAI:4108 chart
P/E
—
P/S
17.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.53%
Rev. gr., 5y
7.95%
Revenues
135m
-12.36%
99,193,000107,904,000155,092,000177,711,000144,988,00090,732,00020,978,00025,021,00053,996,000107,483,00095,485,00091,810,000168,936,000135,465,000162,489,000153,562,000134,576,000
Net income
-58m
L-20.82%
-267,053,000-215,119,000-170,071,000-103,794,000-182,964,000-321,702,000-203,500,000-194,516,000-206,349,000-182,476,000-170,927,000-118,655,000-78,021,000-115,035,000-47,117,000-73,501,000-58,199,000
CFO
-40m
L-20.78%
-107,148,000-193,063,000-171,088,000-164,368,000-123,180,000-33,743,000-131,217,000-756,870,000-151,520,000-141,435,000-121,446,000-147,866,000-68,239,000-59,948,000-54,772,000-50,134,000-39,715,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-counter medications (Class B), and nutritional supplements. Their prominent offerings feature the PG2 Lyophilized injection, specifically designed to alleviate cancer-related fatigue. The company also markets EnerCharge, available both as a formula to boost physical vigor and maintain mental alertness, and as an energy beverage. Another notable product is ReyeasCleanse health food capsules. Furthermore, PhytoHealth extends its expertise to precision medical devices, specialized diagnostic software, and licensing services for computer-aided diagnostic systems.
URL
https://www.phytohealth.com.tw/zh-Hant
IPO date
May 07, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT